Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis

ABSTRACT

Objective: To investigate the mechanisms of vasculitis in nonsystemic vasculitic neuropathy (NSVN) and microscopic polyangiitis (MPA), focusing on complement- and antineutrophil cytoplasmic antibody (ANCA)-associated pathogenesis.

Methods: Sural nerve biopsy specimens taken from twenty-four patients with NSVN and 37 with MPA-associated neuropathy (MPAN) were examined. Twenty-two patients in the MPAN group tested positive for ANCA.

Results: Immunostaining for complement component C3d deposition showed more frequent positive staining of epineurial small vessels in NSVN than in MPAN (p < 0.002). The percentages of C3d-positive blood vessels were higher in the NSVN group than those in the ANCA-positive MPAN and ANCA-negative MPAN groups (p = 0.002 and p = 0.009, respectively). Attachment of neutrophils to the endothelial cells of epineurial small vessels was frequently observed in the MPAN groups, irrespective of the presence or absence of ANCA, but was scarce in the NSVN group. Immunohistochemistry using antymeloperoxidase (MPO) antibodies revealed that the number of MPO-positive cells attached to the endothelial cells of epineurial vessels was lower in the NSVN group than that in the ANCA-positive MPAN and ANCA-negative MPAN groups (p < 0.001 and p = 0.011, respectively).

Conclusions: NSVN and MPA have distinct mechanisms of vasculitis. In MPA, the attachment of neutrophils to vascular endothelial cells seems to be an initial lesion of vasculitis, regardless of the presence or absence of ANCA. Complement participated in the pathogenesis of vasculitis in NSVN.

Neurol Neuroimmunol Neuroinflamm 2017;4:e407; doi: 10.1212/NXI.0000000000000407

GLOSSARY

ANCA = antineutrophil cytoplasmic antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; MPA = microscopic polyangiitis; MPO = myeloperoxidase; MPAN = MPA-associated neuropathy; NSVN = nonsystemic vasculitic neuropathy; PBS = phosphate-buffered saline; PR3 = proteinase 3.

Vasculitides are diseases caused by the inflammation of vessels. They affect a variety of vessels, ranging from the aorta to capillaries in a variety of organs.1 The lungs, heart, kidneys, gastrointestinal tract, skin, and nervous system are frequently involved in vasculitides.2,3 In the peripheral nervous system, vasculitis usually occurs in small vessels located in the epineurium, leading to ischemia and subsequent axonal degeneration.4,5 Hence, vasculitides affecting small vessels, such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, frequently affect the peripheral nervous system.2,3 For example, microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (previously known as Churg-Strauss syndrome) affect the peripheral nervous system in up to 60%–80% of patients, respectively.2,3,6 In addition to these ANCA-associated vasculitides, ANCA-negative vasculitis confined to the peripheral nervous system has also been reported in neurology and constitutes one of the major clinical categories of vasculitic neuropathy.7–13 Although this disease has been called nonsystemic...
vasculitic neuropathy (NSVN), no consensus exists as to whether NSVN is an independent nosological entity or occurs on a continuum of neuropathies associated with systemic vasculitides. In particular, the distinction between NSVN and MPA is not well defined because the current definition of the latter includes ANCA-negative cases.1,5,11,14

In this study, we examined sural nerve biopsy samples taken from patients with NSVN and MPA, with a particular focus on ANCA- and complement-associated pathogenesis of vasculitis.

METHODS Patients. We retrospectively investigated patients with pathologically confirmed NSVN and ANCA-associated neuropathy (MPAN) who were referred for diagnostic sural nerve biopsy to Nagoya University Graduate School of Medicine between 1997 and 2015. NSVN was diagnosed according to the criteria of the “Peripheral Nerve Society Guidelines for Non-systemic Vasculitic Neuropathy.”13 In the NSVN group, symptoms of vasculitis were confined solely to the peripheral nerves, with no evidence of other organ involvement. Laboratory data also indicated the absence of any other underlying disease, and the erythrocyte sedimentation rate (ESR) was less than 100 mm/h.13 The presence of ANCA was an exclusion criterion for the NSVN group. Inclusion criteria for the MPAN group were based on the definition in the “2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis (CHCC2012).” Involvement of organs other than the nervous system, such as the lungs, skin, heart, gastrointestinal tract, and kidneys, or a positive titer for ANCA was mandatory for inclusion in the MPAN group. ANCA directed against myeloperoxidase (MPO) and proteinase 3 (PR3) were screened by ELISA. The presence or absence of vascular immune deposits was not considered at the time of inclusion.

Subjects meeting criteria for pathologically definite or probable vasculitic neuropathy were included in this study.13 Based on these criteria, 24 patients with NSVN and 37 with MPAN were included. In the ANCA-positive MPAN group, 14 patients had pathologically definite and 8 had probable vasculitic neuropathy. The corresponding diagnoses were 7 and 8 in the ANCA-negative MPAN group and 11 and 13 in the NSVN group. Eleven patients in the NSVN group and 4 in the MPAN group had been included in a previous study.11 Patients with other diseases that may cause vasculitis, such as eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, malignancy-associated vasculitis, or connective tissue disease-associated vasculitis, were excluded.1,13 Patients in the NSVN group were followed up for 4.8 ± 4.7 (mean ± SD) years after diagnosis to confirm that their vasculitis was nonsystemic. Twenty-two of the 37 patients (60%) in the MPAN group were positive for MPO-ANCA; none were positive for PR3-ANCA. All ANCA-negative MPAN patients had findings suggestive of extraneurial involvement. Because these ANCA-negative MPAN patients are particularly controversial from the viewpoint of the distinction from NSVN, subgroups of ANCA-positive MPAN and ANCA-negative MPAN were separately assessed.

Standard protocol approvals, registrations, and patient consent. This study conformed to the Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Japanese government and was approved by the Ethics Committees of Nagoya University Graduate School of Medicine, and all patients provided written informed consent.

Pathologic assessment of sural nerve biopsy specimens. Histopathologic examinations of the sural nerve were performed on all patients under local anesthesia before the initiation of immunotherapy.15,16 The specimens were divided into 2 portions. One portion was fixed in 2.5% glutaraldehyde in 0.125 M cacodylate buffer and embedded in epoxy resin. The density of myelinated fibers was calculated in toluidine blue–stained semithin sections as described previously.15,17 For electron microscopy, epoxy resin–embedded specimens were cut into ultrathin transverse sections and stained with uranyl acetate and lead citrate.18–20 A part of the sample was processed for a teased-fiber study.21 The control values were based on a previous report.22 The second portion of the specimen was fixed in 10% formalin and embedded in paraffin. Sections were sliced using routine methods and then stained with hematoxylin and eosin and Masson trichrome. The investigators who evaluated the biopsies were masked to the clinical diagnosis.

Immunofluorescence and immunohistochemical studies. Immunofluorescence and immunohistochemistry were performed in all samples using serial 4-μm-thick sections from paraffin-embedded specimens. To evaluate vascular complement deposition, indirect immunofluorescence was performed.18–20 Sections were deparaffinized and heated at 98°C for 10 minutes in citrate buffer for antibody retrieval (pH 6.0) and left to cool at room temperature for 10 minutes. Samples were then immersed in 0.3% hydrogen peroxide and washed 3 times with phosphate-buffered saline (PBS). A rabbit monoclonal antibody against complement component C3d (1:50; Abcam, Cambridge, United Kingdom) served as the primary antibody and was dissolved in blocking solution with goat serum and then incubated for 60 minutes at 4°C. After washes with PBS, the sample was incubated for 3 hours at room temperature with Alexa Fluor donkey anti-rabbit IgG (H + L, 1:1,000). The stained sections were examined and photographed using an optical microscope (FSX 100; Olympus, Tokyo, Japan).

To evaluate the location of MPO-positive polymorphonuclear leukocytes, immunohistochemistry was performed via immunoperoxidase staining.23 Sections were deparaffinized and heated at 98°C for 10 minutes in citrate buffer for antibody retrieval (pH 6.0) and left to cool at room temperature for 10 minutes. After immersion in 0.3% hydrogen peroxide, sections were washed 3 times with PBS. Primary antibodies (rabbit polyclonal anti-MPO; 1:100; Abcam) were dissolved in blocking solution containing goat serum and incubated for 60 minutes at 4°C. After washes with PBS, the sections were incubated for 30 minutes at room temperature with anti-rabbit IgG conjugated to biotin, washed again with PBS, and incubated for 60 minutes at 4°C with an avidin-biotin complex.

All epineurial blood vessels in the complete transverse sections of the sural nerve were assessed for immunohistochemical and immunofluorescent studies in each case. The amount of MPO-positive cells attached to the endothelial cells of epineurial vessels was evaluated as the number of these cells per vessel. To identify the initial lesions that led to vasculitis, vessels that retained their morphology were included in the quantitative analyses.

Statistical analysis. Quantitative data are presented as mean ± SD unless otherwise indicated. Statistical analyses were performed using χ² tests or 1-way analysis of variance to assess differences among all 3 groups. Subsequently, the Tukey-Kramer method was used as a post hoc test to identify significant differences
between each pair of patient groups, if necessary. \( p \) Values <0.05 were considered statistically significant.

**RESULTS** Characteristics of patients. The patient characteristics are summarized in table 1 and reported as medians and ranges in table e-1 at Neurology.org/nn. Although the age at biopsy seemed to be younger in the NSVN group than in the MPAN groups, the demographics and neuropathic features in the NSVN and MPAN groups were not significantly different. In the ANCA-positive MPAN group, findings suggestive of renal, pulmonary, cutaneous, and gastrointestinal tract involvement were noted in 32%, 41%, 36%, and 24% of patients, respectively. Two patients in the ANCA-negative MPAN group, these proportions were 40%, 33%, 33%, and 20%, respectively. C-reactive protein (CRP), ESR, and white blood cell counts were higher in the

<table>
<thead>
<tr>
<th>Table 1 Patient characteristics</th>
<th>MPA (all cases) ( n = 37 )</th>
<th>MPA (ANCA positive) ( n = 22 )</th>
<th>MPA (ANCA negative) ( n = 15 )</th>
<th>NSVN ( n = 24 )</th>
<th>( p ) Value(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at biopsy, y</strong></td>
<td>( 64.8 \pm 12.9 )</td>
<td>( 63.5 \pm 14.9 )</td>
<td>( 66.8 \pm 9.5 )</td>
<td>( 58.0 \pm 16.5 )</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Men/women</strong></td>
<td>20/17</td>
<td>10/12</td>
<td>10/5</td>
<td>13/11</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Sensory disturbance</strong></td>
<td>32 (87)</td>
<td>19 (86)</td>
<td>13 (87)</td>
<td>21 (88)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Muscle weakness</strong></td>
<td>5 (14)</td>
<td>3 (14)</td>
<td>2 (13)</td>
<td>3 (13)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Duration of neuropathy, mo(^b)</strong></td>
<td>( 4.8 \pm 4.5 )</td>
<td>( 3.9 \pm 3.7 )</td>
<td>( 6.2 \pm 5.3 )</td>
<td>( 7.9 \pm 7.8 )</td>
<td>NS</td>
</tr>
<tr>
<td><strong>CRP, mg/dL</strong></td>
<td>8.9 ± 7.4</td>
<td>8.4 ± 5.0</td>
<td>9.6 ± 10.2</td>
<td>1.3 ± 2.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>ESR, mm/h</strong></td>
<td>64.0 ± 37.9</td>
<td>76.9 ± 38.6</td>
<td>49.2 ± 32.4</td>
<td>33.9 ± 28.0</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>White blood cell count, no./mm(^3)</strong></td>
<td>( 11,948 \pm 6,674 )</td>
<td>( 10,959 \pm 4,586 )</td>
<td>( 13,398 \pm 8,400 )</td>
<td>( 7,351 \pm 3,602 )</td>
<td>0.007</td>
</tr>
<tr>
<td><strong>C3, mg/dL</strong></td>
<td>112.9 ± 31.4</td>
<td>111.3 ± 27.3</td>
<td>115.3 ± 37.3</td>
<td>99.2 ± 23.4</td>
<td>NS</td>
</tr>
<tr>
<td><strong>C4, mg/dL</strong></td>
<td>28.6 ± 20.2</td>
<td>29.9 ± 24.4</td>
<td>26.8 ± 13.0</td>
<td>25.6 ± 17.0</td>
<td>NS</td>
</tr>
<tr>
<td><strong>CH50, U/mL</strong></td>
<td>42.4 ± 15.1</td>
<td>44.3 ± 13.7</td>
<td>42.5 ± 18.8</td>
<td>42.2 ± 15.3</td>
<td>NS</td>
</tr>
<tr>
<td><strong>CSF protein, mg/dL</strong></td>
<td>36.9 ± 16.9</td>
<td>30.0 ± 8.6</td>
<td>39.5 ± 19.9</td>
<td>44.6 ± 18.1</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Nerve conduction studies(^c)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Median nerve</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMAP, mV</td>
<td>5.1 ± 3.5</td>
<td>6.2 ± 3.7</td>
<td>3.4 ± 2.2</td>
<td>4.7 ± 3.7</td>
<td>NS</td>
</tr>
<tr>
<td>SNAP, ( \mu )V</td>
<td>13.4 ± 13.4</td>
<td>17.0 ± 15.2</td>
<td>7.7 ± 7.3</td>
<td>8.2 ± 10.6</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Tibial nerve</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMAP, mV</td>
<td>2.1 ± 3.6</td>
<td>2.5 ± 4.2</td>
<td>1.6 ± 2.7</td>
<td>5.9 ± 7.0</td>
<td>NS</td>
</tr>
<tr>
<td>SNAP, ( \mu )V</td>
<td>0.9 ± 1.7</td>
<td>0.8 ± 1.8</td>
<td>1.2 ± 1.7</td>
<td>2.4 ± 4.8</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Pathology of the sural nerve(^d)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total MFD, no./mm(^2)</td>
<td>( 2,649 \pm 3,846 )</td>
<td>( 2,619 \pm 4,364 )</td>
<td>( 2,272 \pm 3,208 )</td>
<td>( 2,455 \pm 3,073 )</td>
<td>NS</td>
</tr>
<tr>
<td>Large MFD, no./mm(^2)</td>
<td>( 877 \pm 1,525 )</td>
<td>( 968 \pm 1,814 )</td>
<td>( 758 \pm 1,098 )</td>
<td>( 686 \pm 996 )</td>
<td>NS</td>
</tr>
<tr>
<td>Small MFD, no./mm(^2)</td>
<td>( 1,578 \pm 2,347 )</td>
<td>( 1,651 \pm 2,570 )</td>
<td>( 1,483 \pm 2,118 )</td>
<td>( 1,769 \pm 2,200 )</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Teased-fiber study</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De/remyelination, %</td>
<td>1.2 ± 1.6</td>
<td>1.1 ± 1.7</td>
<td>1.5 ± 1.5</td>
<td>2.7 ± 3.3</td>
<td>NS</td>
</tr>
<tr>
<td>Axonal degeneration, %</td>
<td>70.5 ± 33.2</td>
<td>79.2 ± 29.1</td>
<td>58.6 ± 36.0</td>
<td>58.8 ± 33.1</td>
<td>NS</td>
</tr>
</tbody>
</table>

Abbreviations: ANCA = antineutrophil cytoplasmic antibody; CMAP = compound muscle action potential; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; MFD = myelinated fiber density; MPA = microscopic polyangiitis; NS = not significant; NSVN = nonsystemic vasculitic neuropathy; SNAP = sensory nerve action potential. Data are number [%] or mean ± SD.

\(^a\) One-way analysis of variance (ANCA-positive MPA, ANCA-negative MPA, and NSVN groups).

\(^b\) Duration of neuropathy until sural nerve biopsy.

\(^c\) Control values for CMAP in the median nerve, SNAP in the median nerve, CMAP in the tibial nerve, and SNAP in the sural nerve are \( 8.2 \pm 2.9, 28.0 \pm 11.5, 11.8 \pm 3.5, \) and \( 16.8 \pm 7.8 \), respectively.\(^{16}\)

\(^d\) Control values for total MFD, large MFD, small MFD, de/remyelination, and axonal degeneration are \( 8,247 \pm 737, 3,129 \pm 642, 5,118 \pm 429, 8.6 \pm 6.7, \) and \( 1.8 \pm 1.6, \) respectively.\(^{22}\)
ANCA-positive MPAN and ANCA-negative MPAN groups than in the NSVN group.

Indices of sural nerve biopsy specimens, including the densities of myelinated fibers and the frequencies of segmental de/remyelination and axonal degeneration, were not significantly different among the 3 groups.

Complement deposition on epineurial vessels. We assessed the deposition of complement component C3d around epineurial vessels. Although epineurial vessels that exhibited signs of vasculitis, such as destruction of vessel walls accompanied by inflammatory cellular infiltration, showed some positive anti-C3d antibody staining, some epineurial vessels with preserved morphology also stained positively (figure 1). When we assessed these vessels with preserved morphology, C3d deposition was more frequently observed in patients with NSVN than in those with MPAN (23% of patients in the ANCA-positive MPAN group, 33% in the ANCA-negative MPAN group, and 71% in the NSVN group; \( p = 0.002 \)).

The percentages of C3d-positive epineurial blood vessels in the complete transverse sections of the sural nerve were 2.6 ± 7.2 in the ANCA-positive MPAN group, 3.1 ± 5.2 in the ANCA-negative MPAN group, and 15.7 ± 18.0 in the NSVN group (\( p = 0.001 \), figure 2 and table e-2). The diameters of these vessels were usually 30–70 \( \mu \)m. Serum C3 levels were slightly (but not significantly) lower in NSVN with positive C3d deposition than in that with negative C3d deposition (93 ± 22 mg/dL vs 114 ± 25 mg/dL).

C3d deposition on epineurial vessels was observed in only 10 patients with MPAN, 5 in the ANCA-positive MPAN group and 5 in the ANCA-negative MPAN group. However, the intensity of immunostaining was much weaker in those cases than that in the NSVN cases, corresponding to the CHCC2012 definition of MPA.1 Concerning damage to organs other than the peripheral nervous system, 2 of these cases showed no substantial damage to other organs but were diagnosed as MPA because of positive ANCA. Seven other cases had 1 additionally damaged organ: lung in 1, kidney in

---

**Figure 1** Representative images of complement component C3d immunofluorescence in sural nerve biopsy specimens

A, B, C, D, E, and F are photographs of sural nerve biopsy specimens from patients with ANCA-negative MPAN and ANCA-positive MPAN, respectively. A, B, and C show epineurial vessels that were positively stained with antibodies against C3d in NSVN (A and C), whereas those in MPAN were not stained with these antibodies (E). Phase-contrast microscopy images of A, C, and E are shown in B, D, and F, respectively. Nerve fascicles are indicated by asterisks in B, D, and F. Scale bars = 100 \( \mu \)m.

**Figure 2** The percentage of complement component C3d-positive epineurial blood vessels

All epineurial blood vessels in the complete transverse sections of the sural nerve were assessed in each case. Error bars represent SEM. The percentages of C3d-positive epineurial blood vessels in the complete transverse sections of the sural nerve were 2.6 ± 7.2 in the ANCA-positive MPAN group, 3.1 ± 5.2 in the ANCA-negative MPAN group, and 15.7 ± 18.0 in the NSVN group (\( p = 0.001 \), 1-way analysis of variance). The Tukey-Kramer method revealed significant differences between the ANCA-positive MPAN group and the NSVN group (\( p = 0.002 \)), as well as between the ANCA-negative MPAN group and the NSVN group (\( p = 0.009 \)). No significant difference was seen between the ANCA-positive and ANCA-negative MPAN groups.
2, digestive tract in 1, and skin in 3. Another case showed renal and pulmonary damage in addition to neuropathy. ESRs in these cases were variable, ranging from 35 to 120 mm/h.

Adhesion of neutrophils to epineurial vessels. On routine hematoxylin and eosin–stained sections, polymorphonuclear cells were occasionally detected in the lumina of epineurial small vessels in both the NSVN and MPAN groups. Because the majority of these cells had numerous small granules, these cells were considered to be neutrophils. Polymorphonuclear cells with relatively large eosinophilic granules, that are considered to be eosinophils, were also found in vessel lumina, although the number was much lower than neutrophils in both the NSVN and MPAN groups. Attachment of neutrophils to the endothelial cells of epineurial small vessels was frequently observed in the MPAN groups, irrespective of the presence or absence of antineutrophil cytoplasmic antibodies (A and C), whereas such attachment was scarce in the NSVN group, although polymorphonuclear cells were present in vessel lumina (B and D). MPO-positive cells are indicated by arrowheads. Scale bars = 20 µm.

Quantitative analysis was performed by immunohistochemistry with anti-MPO antibodies. Both neutrophils and monocytes were found to be MPO positive, but light and electron microscopy revealed that monocytes rarely attached to the endothelial cells of epineurial blood vessels in either NSVN or MPAN. The numbers of MPO-positive cells that attached to the endothelial cells of epineurial blood vessels were 0.12 ± 0.08 per epineurial vessel in the ANCA-positive MPAN group, 0.09 ± 0.08 in the ANCA-negative MPAN group, and 0.02 ± 0.04 in the NSVN groups (p < 0.001, figure 5 and table e-2).

Because blood examination revealed higher white blood cell counts in the MPA groups than in the NSVN group, the result was verified by comparing the indices of the number of MPO-positive cells attached to the endothelial cells divided by the bold white blood cell count. It was still significant after this correction (1.14 × 10⁻³ ± 0.89 × 10⁻³ in the ANCA-positive MPAN, 0.81 × 10⁻³ ± 0.72 × 10⁻³ in the ANCA-negative MPAN, and 0.34 × 10⁻³ ± 0.45 × 10⁻³ in the NSVN groups; p = 0.002). Together, these findings suggest that vascular endothelial cell damage by neutrophils is a pathologic
signature of MPAN but not NSVN. Two ANCA-positive patients without apparent involvement of other organs also had attachment of MPO-positive cells to the vascular endothelium (0.31 and 0.09 cells per epineurial vessel). Vascular C3d deposition was not observed in those patients.

Most patients with NSVN had normal or only mildly abnormal laboratory findings, but 1 had significantly elevated inflammatory indices (ESR 76 mm/h and CRP 12.7 mg/dL), with no findings suggestive of other organ involvement. This patient also had increased endothelial attachment of MPO-positive cells (0.18 cells per epineurial vessel) and negative C3d antibody staining.

**DISCUSSION**

NSVN has been proposed by neurologists to be a neuropathy confined to the peripheral nervous system.\(^8\,11\,13\) It is one of the most common causes of vasculitic neuropathy, along with MPA and eosinophilic granulomatosis with polyangiitis.\(^11\,13\,14\,25\) Whether this disease is truly an isolated nosological entity or simply a continuum on the spectrum of systemic vasculitides, particularly small vessel vasculitis including MPA, remains controversial.\(^1\,5\,11\)

The ambiguity of the definition of NSVN seems to result from the absence of specific biomarkers, including autoantibodies. We compared the clinicopathologic features of MPA and NSVN, focusing on immune mechanisms that might trigger vasculitis, and clearly demonstrated differences between these 2 entities. The most notable finding in our study is that C3d deposition was frequently observed at epineurial small vessels in NSVN. Although antibodies triggering complement pathways were not clarified, this finding suggests that the complements participate in the pathogenesis of NSVN but not MPA.

As for the pathogenesis of MPA, attachment of neutrophils activated by ANCA to endothelial cells of small vessels is considered to be an initial trigger of vasculitis.\(^26\) This effect is also clearly demonstrated in our study, which showed this finding in both ANCA-positive and ANCA-negative cases classified as MPA. Regarding complement deposition in the pathogenesis of vasculitis, CHCC2012 nomenclature defines small vessel vasculitides with the participation of complement.\(^1\) However, the CHCC2012 nomenclature does not clearly distinguish NSVN.\(^1\) Therefore, the active participation of researchers in the field of neurology, particularly peripheral neuropathy, in vasculitis research is needed to establish the nosology of NSVN.

According to the initial report, the features of NSVN are defined as follows: (1) clinically, only nerves are affected; and (2) no or few constitutional symptoms or serologic abnormalities are present.\(^8\) More recent guidelines for NSVN, published on behalf of the Peripheral Nerve Society, seem to adopt looser criteria, as they do not exclude patients with constitutional symptoms, such as fever, weight loss, malaise, fatigue, myalgias, and arthralgias.\(^13\) As for laboratory data indicating the severity of inflammation, the criteria included patients with an ESR less than 100 mm/h.\(^13\) In addition, vasculitis detected in muscle biopsy specimens is not considered for exclusion.\(^13\) In this study, we included patients in the NSVN group based on these criteria. Most patients with NSVN had normal or only mildly abnormal laboratory findings, but 1 had elevated inflammatory indices, increased endothelial attachment of neutrophils, and negative C3d antibody staining as described in the Results section. This patient may...
Some patients with MPA may initially present with characteristics indistinguishable from those of NSVN. One patient, who was ultimately diagnosed with MPA, manifested only symptoms suggestive of peripheral nervous system involvement and not systemic involvement for 2 years. Sural nerve biopsy was performed when the patient manifested a recurrence of neuropathy and systemic involvement involving the skin and gastrointestinal tract. Another patient included in the MPAN group was initially diagnosed with NSVN at the time of nerve biopsy, but serum ANCA became positive 4 years later. The specimens from these patients showed attachment of neutrophils to the endothelial cells of small epineurial vessels and negative C3d staining, which are characteristic of MPA, despite the initial diagnosis of NSVN.

Currently, the most commonly used nomenclature for vasculitides is CHCC2012, which was originally published in 1994 to propose names and definitions for the most common forms of vasculitis, including MPA. According to this nomenclature, MPA is defined as vasculitis that affects small blood vessels with few or no immune deposits and is often associated with ANCA. As MPA does not have specific clinical or laboratory characteristics, such as the presence of asthma or eosinophilia in eosinophilic granulomatosis with polyangiitis or granulomatous inflammation in the respiratory tract in granulomatosis with polyangiitis, the diagnosis of MPA depends on the exclusion of other diseases unless immune deposits are evaluated. Although CHCC2012 included the concept of single-organ vasculitis, such as cutaneous small vessel vasculitis, testicular arteritis, and CNS vasculitis, vasculitis confined to the peripheral nervous system was not mentioned. Therefore, the distinction between MPA and NSVN has not yet been clarified based on current nomenclature. As this study suggests that MPA and NSVN are distinct with respect to the mechanism of vasculitis, establishing the position of NSVN in the spectrum of vasculitides on the basis of CHCC2012 nomenclature is needed. The data support targeted therapies based on the mechanisms of NSVN. For example, eculizumab, a recombinant humanized monoclonal antibody that inhibits complement cascades, may be effective in patients with NSVN. Further studies regarding the search for specific biomarkers, such as causative autoantibodies that trigger complement cascades, are also needed to clarify the mechanisms of vasculitis in NSVN.

**AUTHOR CONTRIBUTIONS**

Haruki Koike and Gen Sobue developed the hypotheses and conceived the study. Mie Takahashi, Haruki Koike, Shohei Ikeda, Yuichi Kawagashira, Masahiro Iijima, Atsushi Hashizume, and Masahisa Katsuno compiled and analyzed the clinical data. Mie Takahashi, Haruki Koike, Shohei Ikeda, Yuichi Kawagashira, Masahiro Iijima, and Gen Sobue performed the pathologic analysis. Gen Sobue supervised the study. Haruki Koike wrote the first draft, and all authors critically evaluated the manuscript.

**STUDY FUNDING**

This work was supported by grants from the Ministry of Health, Labor and Welfare (Research on rare and intractable diseases, H26-057) and the Ministry of Education, Culture, Sports, Science and Technology (25461276) of Japan.

**DISCLOSURE**

M. Takahashi reports no disclosures. H. Koike received research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Welfare and Labor of Japan. S. Ikeda, Y. Kawagashira, M. Iijima, and A. Hashizume report no disclosures. M. Katsuno served on the scientific advisory board for Pharmaceutics and medical device agency, Japan; received travel funding and speaker honoraria from Tanabe-Mitsubishi; consulted for Riprocel, Aoh Pharma; holds a patent for nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy and Anti-spinal and bulbar muscular atrophy; and received research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Japan Agency for...
Medical Research and Development. G. Sobue served on the scientific advisory board for the Kanae Science Foundation for the Promotion of Medical Science, the Naito Science Foundation, and the Takeda Foundation; served on the editorial board for Brain, Degenerative Neurological and Neuromuscular Disease, Journal of Neurology, Amyotrophic Lateral Sclerosis; and received research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Welfare, Health and Labor of Japan, The Japan Science and Technology Agency, and Core Research for Evolutional Science and Technology. Go to Neurology.org/nm for full disclosure forms.

Received August 16, 2017. Accepted in final form September 7, 2017.

REFERENCES


Distinct pathogenesis in non-systemic vasculitic neuropathy and microscopic polyangiitis
Mie Takahashi, Haruki Koike, Shohei Ikeda, et al.
Neurol Neuroimmunol Neuroinflamm 2017;4;
DOI 10.1212/NXI.0000000000000407

This information is current as of October 23, 2017